. 2014 May 1;24(4):190–200. doi: 10.1089/cap.2013.0043

Table 3.

Conners Comprehensive Behavior Rating Scales (MMRM): Efficacy Analyses Data Set^a,b

	Placebo (n=63)		Edivoxetine 0.1 (n=58)		Edivoxetine 0.2 (n=60)		Edivoxetine 0.3 (n=59)		OROS MPH^c (n=26)
Comorbid symptoms measure (CBRS)	Baseline	Change at end-point	Baseline	Change at end-point	Baseline	Change at end-point	Baseline	Change at end-point	Baseline	Change at end-point
ODD	69.1	−7.2	72.0	−4.0	66.9	−10.2	71.1	−12.3^*	70.5	−13.8
Generalized anxiety	71.9	−9.1	73.8	−5.3	71.4	−11.1	73.3	−15.4^*	70.4	−8.8
Separation anxiety	55.9	−6.7	58.7	−1.1^*	60.5	−5.9	57.8	−8.6	59.4	−2.9
Conduct disorder	61.1	−4.6	65.8	−2.2	58.3	−6.3	62.7	−7.6	58.8	−7.1
Manic episode	76.1	−9.4	77.3	−5.0	73.6	−12.6	78.4	−12.4	75.8	−11.9
Social phobia	58.3	−6.8	59.8	−2.2^*	58.8	−6.1	60.1	−10.0	61.3	−3.1
Major depressive episode	69.6	−10.3	71.9	−5.4^*	69.4	−9.6	69.8	−13.7	67.0	−1.1

^{^a}

Change scores expressed as least-squares means.

^{^b}

CBRS symptom scores are expressed as t scores, based on age and gender norms.

^{^c}

Patients who received OROS MPH were in the stimulant-naïve strata only.

^{^*}

p<0.05 vs. placebo

0.1=0.1 mg/kg/day; 0.2=0.2 mg/kg/day; 0.3=0.3 mg/kg/day.

CBRS, Conners Comprehensive Behavior Rating Scales; MMRM, mixed model repeated measures; ODD, oppositional defiance disorder; OROS MPH, osmotic-release oral system methylphenidate.